Staidson Beijing Biopharma Total Assets
Staidson Beijing Biopharma total assets. Based on the latest financial reports, Staidson Beijing Biopharma (300204) holds total assets worth CN¥1.28 Billion CNY (≈ $187.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300204 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Staidson Beijing Biopharma (2007–2025)
Total assets of Staidson Beijing Biopharma from 2007 to 2025. This chart illustrates how Staidson Beijing Biopharma's total assets have evolved over time, based on quarterly financial data. See 300204 live share price for real-time trading data and today's change.
Staidson Beijing Biopharma - Asset Composition Analysis
Staidson Beijing Biopharma Total Assets Breakdown (December 2025)
Staidson Beijing Biopharma total assets breakdown as of December 2025. Staidson Beijing Biopharma's total assets of CN¥1.28 Billion consist of 20.0% current assets and 80.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.8% |
| Accounts Receivable | CN¥24.13 Million | 1.9% |
| Inventory | CN¥19.30 Million | 1.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥222.33 Million | 17.6% |
| Goodwill | CN¥19.75 Million | 1.6% |
Asset Composition Trend (2007–2025)
This chart illustrates how Staidson Beijing Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Staidson Beijing Biopharma's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Staidson Beijing Biopharma's current assets represent 20.0% of total assets in 2025, a decrease from 46.7% in 2007.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 16.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, a decrease from 24.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 17.6% of total assets.
Staidson Beijing Biopharma Competitors by Total Assets
Key competitors of Staidson Beijing Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Staidson Beijing Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 1.59 | 4.92 |
| Quick Ratio | 1.85 | 1.40 | 4.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥131.32 Million | CN¥83.76 Million | CN¥619.94 Million |
Staidson Beijing Biopharma - Advanced Valuation Insights
This section examines the relationship between Staidson Beijing Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.05 |
| Latest Market Cap to Assets Ratio | 1.09 |
| Asset Growth Rate (YoY) | 10.1% |
| Total Assets | CN¥1.27 Billion |
| Market Capitalization | $1.37 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Staidson Beijing Biopharma's assets above their book value (1.09x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Staidson Beijing Biopharma's assets grew by 10.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Staidson Beijing Biopharma (2007–2025)
The table below shows the annual total assets of Staidson Beijing Biopharma from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.27 Billion ≈ $185.29 Million |
+10.14% |
| 2024-12-31 | CN¥1.15 Billion ≈ $168.22 Million |
-13.71% |
| 2023-12-31 | CN¥1.33 Billion ≈ $194.95 Million |
-20.19% |
| 2022-12-31 | CN¥1.67 Billion ≈ $244.27 Million |
-8.63% |
| 2021-12-31 | CN¥1.83 Billion ≈ $267.35 Million |
-1.57% |
| 2020-12-31 | CN¥1.86 Billion ≈ $271.62 Million |
-0.33% |
| 2019-12-31 | CN¥1.86 Billion ≈ $272.53 Million |
-32.82% |
| 2018-12-31 | CN¥2.77 Billion ≈ $405.65 Million |
+5.46% |
| 2017-12-31 | CN¥2.63 Billion ≈ $384.64 Million |
+11.82% |
| 2016-12-31 | CN¥2.35 Billion ≈ $343.97 Million |
+13.51% |
| 2015-12-31 | CN¥2.07 Billion ≈ $303.03 Million |
+14.29% |
| 2014-12-31 | CN¥1.81 Billion ≈ $265.14 Million |
+15.45% |
| 2013-12-31 | CN¥1.57 Billion ≈ $229.66 Million |
+9.53% |
| 2012-12-31 | CN¥1.43 Billion ≈ $209.69 Million |
+24.67% |
| 2011-12-31 | CN¥1.15 Billion ≈ $168.19 Million |
+333.93% |
| 2010-12-31 | CN¥264.88 Million ≈ $38.76 Million |
+78.07% |
| 2009-12-31 | CN¥148.75 Million ≈ $21.77 Million |
+61.57% |
| 2008-12-31 | CN¥92.07 Million ≈ $13.47 Million |
+11.98% |
| 2007-12-31 | CN¥82.22 Million ≈ $12.03 Million |
-- |
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respi… Read more